All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How can MRD kinetics assessment help with treatment decisions during maintenance therapy?

During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Bruno Paiva, University of Navarra, Pamplona, ES. We asked, How can measurable residual disease (MRD) kinetics assessment help with treatment decisions during maintenance therapy?

In this video, Paiva discusses the role of assessing MRD kinetics data in optimizing treatment management in the maintenance setting.

 

Share:

Your opinion matters

Did you have similar results to the LYRA trial in clinical practice with DARA+VCd? In which setting?
5 votes - 3 days left ...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox